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Background and aims: The infusion of enriched CMV-specific donor T-cells appears to 
be a suitable alternative for the treatment of drug-resistant CMV reactivation or de novo 
infection after both solid organ and hematopoietic stem cell transplantation. Antiviral 
lymphocytes can be selected from apheresis products using the CliniMACS Cytokine-
Capture-System® either with the well-established CliniMACS® Plus (Plus) device or with 
its more versatile successor CliniMACS Prodigy® (Prodigy).
Methods: Manufacturing of CMV-specific T-cells was carried out with the Prodigy and 
Plus in parallel starting with 0.8–1 × 109 leukocytes collected by lymphapheresis (n = 3) 
and using the MACS GMP PepTivator® HCMVpp65 for antigenic restimulation. Target 
and non-target cells were quantified by a newly developed single-platform assessment 
and gating strategy using positive (CD3/CD4/CD8/CD45/IFN-γ), negative (CD14/CD19/
CD56), and dead cell (7-AAD) discriminators.
Results: Both devices produced largely similar results for target cell viabilities: 
37.2–52.2% (Prodigy) vs. 51.1–62.1% (Plus) CD45+/7-AAD− cells. Absolute num-
bers of isolated target cells were 0.1–3.8  ×  106 viable IFN-γ+ CD3+ T-cells. The 
corresponding proportions of IFN-γ+ CD3+ T-cells ranged between 19.2 and 95.1% 
among total CD3+ T-cells and represented recoveries of 41.9–87.6%. Within two 
parallel processes, predominantly IFN-γ+ CD3+CD8+ cytotoxic T-cells were enriched 
compared to one process that yielded a higher amount of IFN-γ+ CD3+CD4+ helper 
T lymphocytes. T-cell purity was higher for the Prodigies products that displayed a 
lower content of contaminating IFN-γ− T-cells (3.6–20.8%) compared to the Plus 
products (19.9–80.0%).
Conclusion: The manufacturing process on the Prodigy saved both process and 
hands-on time due to its higher process integration and ability for unattended oper-
ation. Although the usage of both instruments yielded comparable results, the lower 
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INtRodUCtIoN
The adoptive transfer of allogeneic CMV-specific T-cells gains 
clinical importance in the selective elimination of the virus as 
an intervention in CMV infections refractory to conventional 
antiviral treatment in hematopoietic stem cell transplantation 
(HSCT) and solid organ transplantation (SOT) (1). The absence 
and/or delayed onset of in  vivo proliferation of CMV-specific 
T-cells during immune reconstitution in SCT can lead to critical 
conditions of patients facing CMV reactivation or de novo infec-
tion. Correspondingly, the continual immunosurveillance by 
active CMV-specific T-cells as a basic requirement in these 
patients plays an essential role for a relevant clearance of early 
and late CMV infections and reactivations before and after days 
90–100 post-HSCT (2–4).
While the overall response time between therapeutic decision 
and start of therapy impacts therapeutic success, its duration 
depends on both the availability of an eligible and consenting 
donor and the rapid generation of the cellular therapeutic. 
Different strategies for the preparation of allogeneic antigen-
specific T-cells for adoptive transfer have been investigated 
and developed to clinical scale so far (5–10). One promising 
rapid technique involves the short-term ex vivo restimulation 
of virus-specific T-cells from lymphapheresis products collected 
from seropositive donors, followed by the isolation of antiviral 
T-cells based on the secretion of interferon-γ (IFN-γ). Following 
specific activation with defined viral antigens such as pp65, 
T-cells release IFN-γ that is finally targeted for immunomagnetic 
enrichment of the activated T-cell subsets (5, 6, 8, 11). The use 
of pooled synthetic overlapping peptides covering the primary 
structure of the viral antigen results in a wide diversity of anti-
viral CD4+ and CD8+ T-cell subsets, thus overcoming the HLA 
restriction that is characteristic of the second rapid method, 
the reversible major histocompatibility complex (MHC) class I 
multimer technology (5, 12).
The feasibility and compliance to the requirements of good 
manufacturing practices (GMP) of the ex vivo restimulation, 
immunomagnetic labeling, and enrichment of antigen-specific 
T-cells outlined above in clinical scale have been demonstrated 
using MACS® GMP PepTivators (e.g., HCMV pp65) and the 
CliniMACS Cytokine-Capture-System® (CCS®) both, developed 
and commercialized by Miltenyi Biotec GmbH (9, 13, 14).
The reagent system is intended to be used with a platform 
technology of microprocessor-controlled instruments that 
provide for semi-automated thus standardized cell processing in 
disposable closed systems, the well-established CliniMACS® Plus 
device (Plus) and its refined successor, the CliniMACS® Prodigy® 
device (Prodigy). Since the process management and control of the 
Plus device is limited to the liquid handling of intermediates and 
reagents during the immunomagnetic enrichment, process steps 
sensitive to time, temperature, and temperature profile have to be 
operated hands-on offline. With its added temperature-controlled 
centrifugation and cell-culture capabilities, the Prodigy allows for 
the integration of the whole manufacturing process in one device 
promising increased precision while reducing hands-on time. 
In the present study, we compare our results of and experiences 
with the application of the CCS® protocol for the generation of 
clinical-grade CMV-specific T-cells with the Prodigy to those 
we gathered with the Plus as previously published (14), focusing 
on inter-instrument precision by applying established quality 
control (QC) protocols.
MAteRIALs ANd Methods
In order to compare the devices, lymphapheresis product was 
split and 0.8–1 × 109 WBC each were processed on both instru-
ments in parallel. The procedures for donor recruitment, lym-
phapheresis, and selection of the IFN-γ-positive CMV-specific 
T-cells with the Plus device are thoroughly described elsewhere 
(14). Thus, only brief summaries thereof are shown below.
Recruitment of CMV-Reactive t-Cell 
donors and Cell Collection
Medically eligible and specifically suitable donors were recruited 
from alloCELL, the allogeneic T-cell donor registry of Hannover 
Medical School’s (MHH) Institute for Transfusion Medicine as 
previously described (14). Briefly, upon written informed consent, 
>3 × 109 leukocytes were collected by lymphapheresis (LA) from 
three donors, each seropositive for anti-CMV IgG, seronegative 
for anti-CMV IgM, and exhibiting frequencies of >0.03% IFN-
γ+/CD3+ CMV-specific memory T-cells in the peripheral blood 
(PB) and their adequate answer to restimulation as established 
by IFN-γ Enzyme-linked ImmunoSpot Assay (ELISpot) and 
MACS® IFN-γ Cytokine Secretion Assay (CSA).
Clinical Grade of CMV-specific t-Cell 
selection
IFN-γ-secreting CD3+ T-cells specific against peptides cover-
ing the HCMV pp65 antigen were restimulated and enriched 
in compliance with EU GMP using the Plus instrument within 
the legally required manufacturing validation (14), whereas the 
Prodigy runs were carried out within pre-GMP process develop-
ment. In both the settings, the CliniMACS CCS® system including 
reagents and consumables was used following the manufacturer’s 
written instructions (14).
The collected LAs were split and processed in parallel on 
the CliniMACS® Plus device and the Prodigy® instrument. For 
content of residual IFN-γ− T-cells in the target fractions produced with the Prodigy may 
allow for a higher dosage of CMV-specific donor T-cells without increasing the risk for 
graft-versus-host disease.
Keywords: closed GMP-compliant systems, immunoaffinity cell selection, virus-specific t-cells, single platform 
and multicolor flow cytometry, CliniMACs Cytokine-Capture-system
FIGURe 1 | schematic comparison of manufacturing processes for CMV-specific t-cells using CliniMACs® Plus and CliniMACs Prodigy®. Both 
processes are largely comparable for washing, incubation, and centrifugation steps during CCS procedures and the immunomagnetic enrichment of IFN-γ-secreting 
leukocytes. However, the processes via Plus procedure required additional labor steps resulted in a time delay to the next morning. Thus, the Prodigy process 
performance revealed a limited hands-on time period after the process initiation.
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the Plus, 2 × 109 nucleated blood cells were washed for platelet 
reduction (15  min 200 g, ambient temperature, TexMACS® 
GMP medium, Miltenyi Biotec), suspended in 200  ml of the 
same medium and stored overnight in 500ml MACS® GMP 
Cell Differentiation Bags (Miltenyi Biotec) at 37°C and 5% 
CO2. Of these, 1 × 109 viable nucleated cells were used for the 
restimulation and immunoaffinity enrichment procedure as 
previously described (14). In contrast, the preparation with the 
Prodigy was initiated immediately with 1 × 109 viable nucleated 
cells from the native lymphapheresis. Ex vivo restimulation (4 h, 
37°C, 5% CO2) with the GMP-grade CMVpp65 peptide pool 
(MACS® GMP PepTivator® HCMV pp65, 1 μg/ml per peptide, 
Miltenyi Biotec), labeling of WBCs with the CliniMACS CCS® 
Catchmatrix Reagent (37°C, 5% CO2), cooling and cooled 
centrifugation steps (2–6°C), and labeling were carried out 
manually with the Plus and autonomously within the Prodigy 
instrument. Finally, the enrichment of IFN-γ-secreting cells 
was performed via immunomagnetic separation (Plus and 
Prodigy) by antibody-conjugated super-paramagnetic particles 
(CliniMACS IFN-γ Enrichment Reagent, Miltenyi Biotec). All 
washing, incubation, and centrifugation steps during CCS® 
processes on both separation devices utilized CliniMACS PBS/
EDTA buffer. Figure 1 summarizes the manufacturing steps of 
the comparative procedures.
Quality Control: Cell enumeration and 
Phenotypic Analysis
The QC applied to the validation runs with the Plus system was 
performed according to the correspondingly validated standard 
operating procedures as shown by Tischer et  al. (14). Briefly, 
the estimation of viability (trypan blue exclusion) and number 
of cells constituting the comparatively cell-poor target fraction 
[positive fraction (PF)] was carried out microscopically. The 
other fractions, e.g., LA, preselection (PreS) were defined as 
the cell fraction after restimulation and labeling immediately 
before immunomagnetic separation, and the negative fraction 
(NF) were analyzed for viability by flow cytometry [7-aminoac-
tinomycin D (7-AAD)], whereas cell enumeration was per-
formed with an automated Hemocytometer (Coulter ACTdiff, 
Beckman Coulter). For phenotyping, six-color flow cytometry 
(BD FACSCanto™ II, BD Biosciences) was used in this dual-
platform setting.
In accordance with the requirements of the European 
Pharmacopoeia’s monography for the “numeration of CD34/
CD45+ cells in hematopoietic products” (EP 2.7.23) a new 
no-wash, single-platform 9-color flow cytometric assay was 
developed to analyze the different cell fractions on a 10-color 
flow cytometer (Navios, Beckman Coulter) resulting from 
process establishment runs on the Prodigy. In vitro diagnostic 
(IVD)- and/or analyte-specific reagent (ASR)-labeled, fluores-
cence-conjugated monoclonal antibodies (mABs), especially 
anti-CD3 [phycoerythrin-cyanin-7 (PC-7)], anti-CD56 (phyco-
erythrin-Texas Red, ECD), anti-CD8 [allophycocyanin (APC)], 
anti-CD19 (APC A700), anti-CD4 (APC A750), anti-CD14 
(Pacific Blue), and anti-CD45 (Krome Orange), were utilized for 
the phenotyping of different leukocyte subpopulations by flow 
cytometric analysis. All mABs were purchased from Beckman 
Coulter with the exception of IFN-γ [phycoerythrin (PE); 
Miltenyi Biotec] for the detection of the IFN-γ-labeled target 
cells. Additionally, dead cells were identified by 7-AAD staining 
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in the same panel, whereas cell debris was discriminated by the 
cells’ forward scatter (FS) and side scatter (SS) properties as well 
as by adjusting the cell discriminator (similar to the threshold 
function of other manufacturers’ software) integrated in the 
Beckman Coulter software (Navios™ Cytometry List Mode 
Data Acquisition and Analysis software). After the labeling of 
samples with multiple mABs (15  min, ambient temperature) 
and subsequent red blood cell lysis (15 min, ambient tempera-
ture, IOTest 3, Beckman Coulter) with 5,000–10,000 cells per 
microliter, total event numbers of at least 100,000 (cell-rich LA, 
PreS, and NF) or 10,000 (cell-poor PF) were acquired for the 
7-AAD− and CD45+ leukocyte regions (Figure 2). Finally, the 
IFN-γ+ (CD4+/CD8+) T-cells and contaminating IFN-γ− leuko-
cyte subsets were analyzed.
statistical Analysis
For graphical and statistical evaluation, the GraphPad Prism 
software v6.02 (GraphPad, San Diego, CA, USA) was used. 
Data sets of all runs were analyzed individually for recovery, 
restimulation frequencies, residual/contaminating leukocytes, 
and viability of target and non-target cells in the different 
fractions and compared between corresponding runs on both 
instruments. Unless otherwise declared, results of the statisti-
cal evaluations are indicated as median with range within the 
individual text modules.
ResULts
selection of CMV-specific t-Cells Using 
the New Fully Automated Prodigy
The feasibility of clinical-scale manufacturing of CMV-specific 
T-cells using the Prodigy instrument could be shown successfully. 
A novel single-platform nine-color flow cytometry protocol was 
established in order to quantify CMV-specific IFN-γ+ T-cells and 
various leukocyte subpopulations in the different fractions (LA, 
PreS, PF, and NF) during the process as exemplarily shown in 
Figure 2.
The quantification of PFs resulted a median yield of 1.5 × 106 
(range: 0.21–9.6) of total viable CD45+ cells and 0.9  ×  106 
(range: 0.14–4.8) of total viable CD3+ T-cells over all process 
runs (Table  1). The range of viable IFN-γ+CD4+ T-cells and 
IFN-γ+CD8+ T-cells was measured between 0.01–0.7 × 106 and 
0.1–3.1 × 106 cells, respectively. Additional parameters character-
izing PF and LA of the three Prodigy processes are compiled for 
individual comparison in Table 1.
The restimulation of donor-derived CMV-specific T-cells by 
antigen incubation was quantified by calculating the ratio of 
absolute numbers [×106] of IFN-γ+CD3+ T-cells and (CD4+ and 
CD8+) T-cell subsets of PreS fractions and the corresponding 
T-cell fractions of the non-stimulated LA (PreS:LA = restimula-
tion factor) as indicated in Table  2 for IFN-γ+ (CD3+/CD4+/
CD8+) T-cells. The median total cell numbers of IFN-γ+CD3+ 
T-cells and (CD4+ or CD8+) T-cell subsets were as follows: IFN-
γ+CD3+ T-cells: 1.6  ×  106, range: 0.4–4.4; IFN-γ+CD3+CD4+ 
T-cells: 1.3 × 106, range: 0.2–1.4; and IFN-γ+CD3+CD8+ T-cells: 
0.3 × 106, range: 0.2–3.0, respectively (Figure 3).
CMV-Antigen-specific t-Cell separation 
Using Plus Compared to Prodigy
Both Plus and Prodigy procedures were assessed with respect 
to yield and efficiency of the enrichment of CMV-responsive 
T-cells. Cell recovery, viability, and numbers of IFN-γ+ and 
IFN-γ− T-cells, and T-cell subsets were analyzed in all process 
fractions.
Starting with a median of 1.6 × 106 viable IFN-γ+CD3+ T-cells 
in the PreS fraction (Figure 3A), the immunomagnetic separa-
tion by Prodigy led to 0.9 ×  106 (range: 0.1–3.8) IFN-γ+CD3+ 
T-cell (Figure 4A) corresponding to a median recovery of 54.4% 
(range: 41.3–87.6%) compared to the median recovery of 77.7% 
(range: 41.9–83.9%) over all Plus processes (Table 3). The purity 
calculated as the percentage of IFN-γ+CD3+ T-cells of total 
CD3+ T-cells in the final PF products showed a median of 84.8% 
(range: 78.2–95.1%, calculated from Table  1) for the Prodigy 
processes compared to a median of 63.1% (range: 19.2–81.2%) 
in the Plus runs (14), respectively. Moreover, the medians of 
viability for recovered CD45+ cells were comparable for both 
procedures: median of Prodigy: 47.8% (range: 37.2–52.2%) and 
median of Plus processes 58.9% (range: 51.1–62.1%) as depicted 
in Figure 4B.
The recovery of IFN-γ+ CD4+ and CD8+ T-cell subsets 
in the PF as the final product compared to the PreS fractions 
varied for both instruments. The median recovery was 48.2% 
(range: 12.7–60.0%) for IFN-γ+CD4+ T-cells and 87.5% (range: 
64.0–100%) for IFN-γ+CD8+ T-cells on the Prodigy compared 
to corresponding medians of 69.9% (range: 11.0–125.4%) and 
of 70.4% (range: 30.2–71.1) on the Plus instrument (Table  3). 
CD4+ to CD8+ T-cell ratios reversed during processing from a 
median of 1.2 (range: 1.02–2.0) in the LA to a median of 0.32 
(range: 0.26–6.64) in the PF of the Prodigy processes (Table 1). 
In the same context, two of three Prodigy products presented 
higher enrichment ratios for IFN-γ+ CD3+CD8+ T-cells than for 
the IFN-γ+CD3+CD4+ subset (CD4 to CD8 ratio from 1:5.2 to 
1:9.8). Only one process run yielded more IFN-γ+ CD3+CD4+ 
T-cells (CD4 to CD8 ratio of ≥6.8:1).
Residual Non-target Cells in end Products 
Using Both Plus and Prodigy Procedures
Residual IFN-γ− leukocyte subpopulations were analyzed as 
known contaminants in each PF and as a quantitative control 
of recovery also in the NFs derived from both instruments. 
Contaminating IFN-γ− T-cells ranged from 3.6 to 20.8% 
(Prodigy) and 18.9 to 80.8% (Plus) among total T-cells in the 
final products. Accordingly, the median total cell number of 
IFN-γ−CD3+ T-cells was 0.04  ×  106 (range: 0.01–1.1) with 
the Prodigy procedure (Table  1) compared to a median of 
0.33  ×  106 (range: 0.23–0.67) in Plus runs (14). Moreover, 
all PFs originating from both procedures contained residual 
CD56+CD3+ (NK-T) cells and CD56+CD3− (NK) cells ≤1.5% 
gated on viable CD45+ cells. However, these contaminants were 
outnumbered in all PFs of both procedures by residual CD14+ 
monocytes and CD19+ B-cells (Prodigy: median [CD14+ cells]: 
26.2%, range: 11.8–38.0, median [CD19+ cells]: 10.8%, range: 
4.6–29.0; Plus: median [CD14+ cells]: 26.7%, range: 16.3–29.9, 
FIGURe 2 | Gating strategy: flow cytometric quality control for the quantification of IFN-γ+ and IFN-γ− (Cd3+/Cd4+/Cd8+) t-cells. 
(Continued)
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FIGURe 2 | Continued.  
Samples from different process fractions (LA, PreS, PF, and NF) were stained with monoclonal antibodies to detect IFN-γ+ (CD3+/CD4+/CD8+) T-cells and 
analyzed by a no-wash, single-platform procedure based on a nine-color flow cytometric protocol. Therefore, CD45−, 7-AAD+, and non-specifically stained debris 
assessed by low forward and side scatter (FS/SS) signals were excluded from viable CD45+ cells (WBC). One histogram illustrates the events of the region 
“beads” along the time course to calibrate the events for cells/μl and detect even sample flow (A,B, LA, and PF, upper rows). For the detection of T- and B-cells, 
the pre-analyzed viable CD45+ cells were used to identify both lymphocyte subsets based on CD3 or CD19 surface expression. Therefore, FS/SS dot plots are 
linked with the region “MNC” (upper row) to exclude debris and outline the correct lymphocyte regions (A,B, LA, and PF, middle rows). Dump channels allowed to 
separate (CD3 vs. CD56) NK-T (CD3+CD56+) and NK (CD3−CD56+) cells (black arrows) from the viable CD45+ cells (especially viable CD56−CD3+ T-cells) to 
identify IFN-γ+ (CD3+/CD4+/CD8+) T-cells (A,B, LA, and PF, lower rows). Exemplarily shown by the analyses of PreS, PF, and NF of one manufacturing process is 
the bordering between IFN-γ− and IFN-γ+ (CD3+/CD4+/CD8+) T-cells (indicated with red arrows, C). To distinguish between CD4+ and CD8+ T-cell subsets, the 
viable CD56−CD3+ T-cells (A,B) were separated by dump channel in CD4+ and CD8+ T-cells (black arrows, C) followed by separations of IFN-γ− and IFN-γ+ 
(CD4+/CD8+) T-cell subsets.
6
Priesner et al. Manufacturing of CMV-Specific T-Cells in GMP-Compliant Systems
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 393
median [CD19+ cells]: 5.1%, range: 4.9–5.9) for both tested 
procedures (Figure  4). Absolute cells numbers [×106] of con-
taminating non-target CD45+ leukocyte subsets are represented 
individually in Figures  4C–F and of IFN-γ− T-cell subsets in 
Table 1. Finally, CD3 negative cell populations of the PreS, PF, 
and NF fractions of all Prodigy runs displayed a negligibly low 
content of less than 0.04% of IFN-γ+ cells among B and NKT/
NK cells or monocytes.
tABLe 2 | Results of antigenic restimulation ex vivo of CMV-specific 
t-cells by Plus and Prodigy procedure.
LA → Pres CliniMACs® Plus CliniMACs Prodigy®
Run 1 Run 2 Run 3 Run 1 Run 2 Run 3
x-fold CD3+IFN-γ+ 6.3 0.2 4.3 44.2 1.4 16.0
x-fold CD4+IFN-γ+ 2.5 0.1 4.0 35.0 1.0 13.1
x-fold CD8+IFN-γ+ 13.7 0.3 28.6 12.3 5.3 30.0
The restimulation factors for CMV-specific T-cells were determined for each run 
by the ratio of flow cytometric total viable IFN-γ+ (CD3+/CD4+/CD8+) T-cells of 
non-stimulated lymphapheresis (LA) and PreS fractions (after ex vivo incubation, 
restimulation, and labeling prior to immunomagnetic enrichment). Restimulation 
carried out using a GMP-grade HCMVpp65 peptide pool (MACS GMP PepTivator 
HCMV pp65, 1 μg/ml per peptide).
tABLe 1 | Comparison of flow cytometric cell counts and subset ratios 
for three clinical-scale CliniMACs Prodigy® procedures using the 
CliniMACs CCs® protocol for the manufacture of CMV-specific t-cells.
LA → PF CliniMACs Prodigy®
Run 1 Run 2 Run 3
LA
Viable CD45+ cells [×109] 1.0 0.8 1.0
Viable CD3+ [×106] 486.2 300.1 167.3
CD4/CD8 ratio (viable CD3+) 1.2 2.0 1.02
PF
Viable CD45+ cells [×106] 9.6 0.21 1.5
Viable CD3+ [×106] 4.8 0.14 0.9
CD4/CD8 ratio (viable CD3+) 0.32 0.26 6.64
Viable IFN-γ+CD3+ [×106] 3.8 0.12 0.9
Viable IFN-γ−CD3+ [×106] 1.1 0.01 0.04
CD4/CD8 ratio (viable IFN-γ+CD3+) 0.2 0.1 6.2
Viable IFN-γ+ CD3+CD4+ [×106] 0.6 0.01 0.7
Viable IFN-γ−CD3+CD4+ [×106] 0.4 0.01 0.03
Viable IFN-γ+ CD3+CD8+ [×106] 3.1 0.1 0.1
Viable IFN-γ−CD3+CD8+ [×106] 0.3 0.01 0.01
Absolute numbers [×106] of viable CD45+ cells, IFN-γ+ and IFN-γ− T-cells (CD3+/CD4+/
CD8+), and T-cell ratios (CD4+/CD8+) of lymphapheresis (LA) and positive fractions 
(PFs) derived from three healthy CMV seropositive donors displayed individually for 
each manufacturing run.
Absolute yields of target cells were 0.1–3.8 × 106 viable IFN-γ+CD3+ T-cells subdivided 
into IFN-γ+CD4+ T-cells (0.01–0.7 × 106) and IFN-γ+CD8+ T-cells (0.1–3.1 × 106) (bold 
numbers).
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Advantages and disadvantages  
of the Manufacturing Process steps 
for Clinical-Grade CMV-specific t-Cells 
by Plus and Prodigy
Figure 1 gives a graphical comparison of the CCS® process flows 
between the two setups investigated. Ignoring the collection and 
logistics of the LA and the QCs of starting material and product, 
the manufacturing sequence can be divided independently of 
instrumentation into the thrombocyte depletion of the starting 
material, its incubation under physiological conditions, antigenic 
restimulation, the consequent IFN-γ secretion and its immedi-
ate immunosorbent capture on the IFN-γ+ cells’ surface, the 
paramagnetic immunolabeling of the secreted IFN-γ captured, 
and the magnetic enrichment of the labeled cells. The process 
includes frequent washes and solvent exchanges as well as a 
precise control of temperature profiles and durations – essential 
during cytokine capture and paramagnetic labeling to prevent 
a premature saturation of the bispecific cytokine catch matrix 
(anti-CD45, anti-IFN-γ) and the anti-IFN-γ-labeled dextran-
derivatized iron oxide particles by solute IFN-γ that would 
compromise product purity and process yield. Whereas the Plus 
procedure’s automation was restricted to the magnetic enrich-
ment step, the Prodigy handled the whole protocol autonomously 
to a large extent. Given the procedure’s complexity, increased 
process integration unsurprisingly resulted in substantially 
reduced hands-on time (approximately 3 man-hours Prodigy 
vs. approximately 12 man-hours Plus; time for the transfer to 
and from the clean room, the preparation of media, and the 
execution of QCs excluded for both setups), rendering irrelevant 
the increase in system setup due to the Prodigies more complex 
tubing set (Prodigy, TS 500: 1.5 man-hours vs. Plus, standard: 0.5 
man-hours). Our first experiences showed that the Prodigy may 
allow for single-handed routine operation – unless the four-eyes 
principle has to be observed, e.g., as a control of the correct 
installation of the tubing set – whereas up to three qualified 
operators had to work in parallel on critical and complex offline 
sub-processes characteristic of the Plus setup. Apart from one 
optional in-process control (IPC) sampling prior to magnetic 
separation (PreS), hands-on time for the Prodigy was limited 
to pre- and post-processing, while scattered over the whole Plus 
process – leaving out only incubation and antigenic restimula-
tion. Total process duration (Prodigy: approximately 20  h vs. 
Plus: approximately 26  h, manufacturer’s instructions: ≤36  h) 
was subject to organizational issues: the regular arrival of the 
LAs in the afternoons and the restriction to working hours 
reasonable for one-shift operations resulted in the programing 
of the Prodigy to 9–11  h of incubation time (manufacturer’s 
instructions: ≥4 h), allowing for optional IPC sampling already 
before magnetic enrichment of the target cells at the beginning 
of the workday. Under the same rationale, the incubation time 
of the Plus process had to be regularly set to ≥16 h (overnight) 
due to the fact that even antigenic restimulation required manual 
initiation. Though not of practical value, process times for both 
setups were in the same range (approximately 10 h, mandatorily 
including 4  h of antigenic restimulation) when corrected for 
this imparity.
dIsCUssIoN
Case reports strongly indicate that patients with viral reacti-
vation or de novo infection post SCT and SOT refractory to 
conventional antiviral treatment benefit from the infusion of 
allogeneic antigen-specific T-cells (2–4). Further investigation 
requires a rapid and economic supply with adequate doses of 
this individual cellular therapeutic in clinical grade. During the 
GMP-compatible establishment of the manufacture of CMV-
specific T-cells with the CCS® on the CliniMACS® Plus instru-
ment, we identified the long duration and poor integration of 
the process as factors possibly compromising these objectives. 
In parallel to the subsequent GMP-compliant validation of 
this process (14), we therefore subjected split starting mate-
rial of three consecutive Plus runs to same procedure on the 
CliniMACS® Prodigy.
FIGURe 3 | Comparison of ex vivo restimulation of CMV-specific t-cells by antigenic restimulation by platform. Restimulation frequencies of CMV-
specific T-cells were compared between all manufacturing processes of Plus and Prodigy. Samples were collected from the PreS fractions after incubation (4 h, 
37°C, 5% CO2) with the HCMVpp65 peptide pool (MACS GMP PepTivator HCMV pp65, 1 μg/ml per peptide). Flow cytometric analyses were performed to identify 
total IFN-γ+-releasing CD3+ T-cells (A) and (CD4+/CD8+) T-cell subsets (B,C) in those PreS fractions to compare both restimulation procedures.
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FIGURe 4 | Comparison of absolute cell counts and viability of enriched CMV-specific t-cells and contaminating residual non-target leukocytes. 
Flow cytometry data of positive fractions from all three healthy CMV-positive donors are shown for each manufacturing run of CMV-specific T-cells selection using 
the CliniMACS® Plus and Prodigy® procedures. Individual values are presented for both platforms including (A) the total numbers [×106] of viable IFN-γ+ (CD3+) 
T-cells, (B) cell viability of PF (%) and residual non-target subsets in relation to CD45+/7-AAD− cells in the PF [(%) (C–F)].
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tABLe 3 | Comparative findings of both Plus and Prodigy process runs 
for the separations of CMV-specific t-cells.
Pres → PF CliniMACs® Plus CliniMACs Prodigy®
Run 1 Run 2 Run 3 Run 1 Run 2 Run 3
CD3+IFN-γ+ 
recovery (%)
83.9 41.9 77.7 87.6 41.3 54.4
CD4+IFN-γ+ 
recovery (%)
69.9 11.0 125.4 48.2 12.7 60.0
CD8+IFN-γ+ 
recovery (%)
71.1 30.2 70.4 100 87.5 64.0
Viability (%) 51.1 62.1 58.9 52.2 37.2 47.8
Process performance was evaluated by the recovery (%) and viability (%) of IFN-γ+ 
(CD3+/CD4+/CD8+) T-cells in target (PF) and CMV restimulated before immunomagnetic 
enrichment (PreS) of clinical-scale CliniMACS CCS® runs with Plus and Prodigy. The 
viability of cells was assessed by 7-AAD staining and flow cytometry.
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Using the Prodigy reduced the process time to 75% of that nec-
essary for the Plus procedure. A further decrease to 60% would 
be possible by shortening the initial incubation time toward its 
specified minimum while simultaneously omitting the only IPC 
of the Prodigy process (PreS), the latter anyhow dispensable due 
to the virtual lack of corrective measures at this stage. Lowering 
the process time from approximately 26 h to approximately 15 h 
(i.e., overnight) in combination with the simultaneous reduction 
of hands-on offline time to 25% of that necessary for the Plus 
process and its restriction to potentially single-handed pre- and 
post-processing with the Prodigy is also clinically relevant: 
process automation and integration make up for one working 
day between apheresis and transfusion, thus either increasing the 
Prodigies product’s operational shelf life or reducing the time to 
its application.
From a different angle, automation and integration not consist-
ently backed by IPC and largely inaccessible to manual interven-
tion even in supervised operation necessitate process precision 
and robustness. In agreement with recent publications (15), our 
QC results support an adequate degree of standardization.
To compare the two setups, we established a no-wash, single-
platform procedure based on 10-color flow cytometry to analyze 
the cellular composition and viability in process intermediates 
and by-/products (LA, PreS, PF, and NF) of all three CliniMACS 
CCS® manufacturing processes.
While the efficiency of restimulation was similar between 
both instruments by total IFN-γ+ T-cells, we found their median 
recovery (Prodigy: 60.0 vs. Plus: 70.4%) and viability (Prodigy: 
47.8 vs. Plus: 58.9%) to be tending lower with the Prodigy but in 
overall agreement with recent reports (16, 17).
In summary, viabilities as well as viable concentrations and 
numbers of both target and residual non-target cells in the final 
product were low but consistent with previous reports (14, 16, 17). 
The low viability does not result from process-related cell death 
but is the arithmetic consequence of very low starting frequen-
cies of target cells combined with the unavoidable co-elution of 
dead cells also unspecifically retained on the tubing set’s column. 
Therefore, the introduction of an additional washing step to the 
Prodigies process matrix post-restimulation and labeling, but 
prior to immunomagnetic enrichment, aiming at the depletion 
of non-viable target and non-target cells should be considered.
Despite the slightly lower target cell recovery, we observed 
an increased median purity of the Prodigies products regarding 
IFN-γ+ T-cells among CD3+ T-cells (Prodigy: 84.8 vs. Plus: 63.1%) 
again correlating with other laboratories’ experiences (15–17). 
However, the observed variability in IFN-γ+ T-cell yield with both 
platforms is indicative for the donor-specific heterogeneity in 
target T-cell frequency and antigenic responsiveness (Figure 4A), 
as previously described for variable ranges of purity and recovery 
of antigen-specific T-cells (15, 16). In our comparative study, both 
procedures showed a tendency to higher ranges of restimulation 
frequencies from IFN-γ+CD3+CD8+ T-cells (Plus: 0.3- to 28.6-
fold; Prodigy: 5.3- to 122.5-fold) than of IFN-γ+CD3+CD4+ 
T-lymphocytes (Plus: 0.1- to 4.0-fold; Prodigy: 1.0- to 35.0-
fold). Interestingly, two Prodigy runs predominantly yielded 
IFN-γ+CD3+CD8+ T-cells compared to IFN-γ+CD3+CD4+ cells, 
whereas the remaining product contained more IFN-γ+ helper 
T-cells than cytotoxic T-cell subsets. Contrary to these results, 
the percentage of IFN-γ+CD3+CD8+ T-cells was higher than that 
of IFN-γ+CD3+CD4+ cells in all three Plus validation runs (14). 
However, similar shifts of IFN-γ+ CD4/CD8 ratios in Prodigy 
target cell products after immunomagnetic separations were 
reported by Bunos et al. in five Prodigy runs (16), which could 
be explained by donor-specific differential stabilities/vitalities of 
restimulated IFN-γ+ T-cell subsets after 4 h of antigen incubation. 
To ensure the efficacy, it is necessary to both stimulate cytotoxic 
CD8+ T-cells and induce a Thelper-1 (Th1) response persisting 
in vivo as well as the rapid acquisition of appropriate donors and 
a consistent and well-established record for the manufacturing of 
virus-specific T-cells with short-term ex vivo activation. The latter 
is aimed at persistent Th1 immunity (18). In summary, we could 
show that the CCS® produced a mixture of antigen-specific CD4+ 
and CD8+ T-cells with both platforms.
Contaminating, potentially alloreactive (IFN-γ−) T-cell 
quantities were less prominent in Prodigy products than in 
Plus [Prodigy 3.6–20.8 vs. Plus: 19.9–80.0% (14)], which may 
contribute to improved prevention of the GvHD in recipients. 
Thus, the Prodigy appears to be at least a platform as adequate for 
the execution of the CCS® procedure as the less integrated Plus 
in terms of both purity of antigen-specific T-cells and number of 
contaminating IFN-γ− T-cells.
Further analyses of residual non-target leukocyte subsets 
revealed similar low levels of viable CD3−CD56+ NK cells and 
CD3+CD56+ NKT-cells but increased numbers of CD14+ mono-
cytes and CD19+ B-cells in products of both platforms (Figure 4). 
One can assume that this carryover of both monocytes/B-cells 
and subordinate NK/NKT cells is caused by unwanted cross-
saturation of catchmatrix molecules bound to those cells by 
soluble IFN-γ secreted by CMV-responsive T-cells. Given the 
original frequencies of subsequently contaminating populations 
in the starting material, one could estimate the order of magni-
tude of analogous carryover of potentially alloreactive T-cells. 
Future work should focus on the nature of unspecific capture of 
contaminants to efficiently reduce residual monocytes and B cells 
in target cell fractions.
Both platforms allow for the development of various T-cell-
based immunotherapies in different indications (19). Unlike 
applications of unmanipulated donor lymphocyte infusions 
11
Priesner et al. Manufacturing of CMV-Specific T-Cells in GMP-Compliant Systems
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 393
(DLIs), the application of antigen-specific T-cells reduces the risk 
of GvHD or other acute side effects while inducing antiviral T-cell 
reconstitution (8, 20, 21).
In summary, our comparison of Plus and Prodigy showed that 
both methods can be used for the manufacture of potent CMV-
specific T-cells successfully. While the integration and automation 
of the whole process in one platform promotes process precision 
and saves hands-on time, the current setup of the Prodigy does 
not allow for user intervention in case of contingencies. Anyway, 
unattended operation to the advantage of prolonged product 
shelf life would make useful interventions virtually impossible in 
the case of fatal malfunctions affecting, e.g., the process critical 
temperature management due to reaction times too short – 
even if the instrument’s potential-free alarm output would be 
connected to a remote system. Our results support the novel 
platform’s potential for desired autonomous operation. However, 
the suitability of this approach has to be justified individually for 
each process and product irrespective of platform qualification 
and process validation.
CoNCLUsIoN
Although approximately 1  ×  106 absolute target cells were 
collected with both platforms investigated, the product’s cell 
concentration was consistently below 1  ×  106 cells/ml at a 
fixed low volume of 40 ml. The latter not allowing for extended 
analysis a multicolor single-platform flow cytometry protocol for 
comprehensive QC was established. Non-target T-cell quantities 
were efficiently depleted for prevention of GvHD. Both instru-
ments provided cellular product of comparable characteristics, 
including antiviral specificity, and may be used alternatively. 
Independent of the manufacturing platform used and in addition 
to the flow cytometric QCs presented here, the development of 
an assay for specific T-cell activity in vitro predictive for in vivo 
efficacy (i.e., potency assay) remains a major challenge for this 
non-cryopreserved cell-poor product regarding assay time, 
sample size, and clinical relevance.
ethICs stAteMeNt
Informed consent was obtained from all donors as approved by 
the Ethics Committee of Hannover Medical School.
AUthoR CoNtRIBUtIoNs
UK, BE-V, and SK designed the study, while CP, RE, and ST were 
mainly responsible for the performance of the study. More in 
detail, CP, RE, and MM realized the manufacturing of antigen-
specific T-cells. KA, ST, MM, BE-V, UK, and SK carried out the 
quality control analysis including both cell characterization and 
the enumeration of the frequency IFN-γ-secreting cells. LG was 
responsible for the lymphapheresis procedure. CP and SK wrote 
the manuscript, while BM-K, H-GH, RB, LA, UK, and BE-V 
contributed to helpful discussions and the careful approval of the 
final manuscript.
ACKNoWLedGMeNts
This study was supported by grants of the Integrated Research and 
Treatment Center Transplantation (IFB-Tx, Ref. No. 01EO0802 
and 01EO1302) financed by the German Federal Ministry of 
Education and Research as well as the “Alfred und Angelika 
Gutermuth Stiftung” and SFB738: “Optimierung konventioneller 
und innovativer Transplantate”.
ReFeReNCes
1. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor 
and recipient before hematopoietic stem cell transplantation in the era of 
antiviral prophylaxis and preemptive therapy. Blood (2004) 103(6):2003–8. 
doi:10.1182/blood-2003-10-3616 
2. Khanna R, Smith C. Cellular immune therapy for viral infections in transplant 
patients. Indian J Med Res (2013) 138(5):796–807. 
3. Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus 
cell-mediated immunity in transplant recipients with cytomegalovirus viremia. 
Transplantation (2012) 93(2):195–200. doi:10.1097/TP.0b013e31823c1cd4 
4. Lilleri D, Gerna G, Zelini P, Chiesa A, Rognoni V, Mastronuzzi A, 
et  al. Monitoring of human cytomegalovirus and virus-specific T-cell 
response in young patients receiving allogeneic hematopoietic stem cell 
transplantation. PLoS One (2012) 7(7):e41648. doi:10.1371/journal.pone. 
0041648 
5. Rauser G, Einsele H, Sinzger C, Wernet D, Kuntz G, Assenmacher M, et al. 
Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines 
for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 
(2004) 103(9):3565–72. doi:10.1182/blood-2003-09-3056 
6. Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht 
K, et  al. Safe adoptive transfer of virus-specific T-cell immunity for the 
treatment of systemic adenovirus infection after allogeneic stem cell trans-
plantation. Br J Haematol (2006) 134(1):64–76. doi:10.1111/j.1365-2141.2006. 
06108.x 
7. Aissi-Rothe L, Decot V, Venard V, Jeulin H, Salmon A, Clement L, et al. Rapid 
generation of full clinical-grade human antiadenovirus cytotoxic T cells for 
adoptive immunotherapy. J Immunother (2010) 33(4):414–24. doi:10.1097/
CJI.0b013e3181cc263b 
8. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, 
et al. Adoptive transfer of pp65-specific T-cells for the treatment of chemo-
refractory cytomegalovirus disease or reactivation after haploidentical and 
matched unrelated stem cell transplantation. Blood (2010) 116(20):4360–7. 
doi:10.1182/blood-2010-01-262089 
9. Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Chakraverty R, et al. 
Directly selected cytomegalovirus-reactive donor T cells confer rapid and 
safe systemic reconstitution of virus-specific immunity following stem cell 
transplantation. Clin Infect Dis (2011) 52(1):49–57. doi:10.1093/cid/ciq042 
10. Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, 
Teruya-Feldstein J, et al. Adoptive immunotherapy with unselected or EBV-
specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hema-
topoietic cell transplantation. Blood (2012) 119(11):2644–56. doi:10.1182/
blood-2011-08-371971 
11. Khanna N, Stuehler C, Conrad B, Lurati S, Krappmann S, Einsele H, et al. 
Generation of a multipathogen-specific T-cell product for adoptive immu-
notherapy based on activation-dependent expression of CD154. Blood (2011) 
118(4):1121–31. doi:10.1182/blood-2010-12-322610 
12. Kiecker F, Streitz M, Ay B, Cherepnev G, Volk HD, Volkmer-Engert R, et al. 
Analysis of antigen-specific T-cell responses with synthetic peptides – what 
kind of peptide for which purpose? Hum Immunol (2004) 65(5):523–36. 
doi:10.1016/j.humimm.2004.02.017 
13. Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, et al. Adoptive 
transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific t cells as treat-
ment for EBV reactivation and lymphoproliferative disorders after allogeneic 
12
Priesner et al. Manufacturing of CMV-Specific T-Cells in GMP-Compliant Systems
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 393
stem-cell transplantation. J Clin Oncol (2013) 31(1):39–48. doi:10.1200/
JCO.2011.39.8495 
14. Tischer S, Priesner C, Heuft HG, Goudeva L, Mende W, Barthold M, et al. 
Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell 
donors and GMP-compliant manufacturing of antiviral T cells. J Transl Med 
(2014) 12(1):336. doi:10.1186/s12967-014-0336-5 
15. Kumaresan P, Figliola M, Moyes JS, Huls MH, Tewari P, Shpall EJ, et  al. 
Automated cell enrichment of cytomegalovirus-specific T cells for clinical 
applications using the cytokine-capture system. J Vis Exp (2015) (104). 
doi:10.3791/52808 
16. Bunos M, Hummer C, Wingenfeld E, Sorg N, Pfirrmann V, Bader P, et  al. 
Automated isolation of primary antigen-specific T cells from donor 
lymphocyte concentrates: results of a feasibility exercise. Vox Sang (2015) 
109(4):387–93. doi:10.1111/vox.12291 
17. Feuchtinger T, Opherk K, Bicanic O, Schumm M, Grigoleit GU, Hamprecht K, 
et al. Dendritic cell vaccination in an allogeneic stem cell recipient receiving 
a transplant from a human cytomegalovirus (HCMV)-seronegative donor: 
induction of a HCMV-specific T(helper) cell response. Cytotherapy (2010) 
12(7):945–50. doi:10.3109/14653241003587645 
18. Song XT, Turnis ME, Zhou X, Zhu W, Hong BX, Rollins L, et  al. A Th1-
inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol 
Ther (2011) 19(1):211–7. doi:10.1038/mt.2010.223 
19. Van Driessche A, Gao L, Stauss HJ, Ponsaerts P, Van Bockstaele DR, 
Berneman ZN, et al. Antigen-specific cellular immunotherapy of leukemia. 
Leukemia (2005) 19(11):1863–71. doi:10.1038/sj.leu.2403930 
20. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. 
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 
(2011) 365(18):1673–83. doi:10.1056/NEJMoa1106152 
21. Melenhorst JJ, Leen AM, Bollard CM, Quigley MF, Price DA, Rooney CM, 
et  al. Allogeneic virus-specific T cells with HLA alloreactivity do not pro-
duce GVHD in human subjects. Blood (2010) 116(22):4700–2. doi:10.1182/
blood-2010-06-289991 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Priesner, Esser, Tischer, Marburger, Aleksandrova, Maecker-
Kolhoff, Heuft, Goudeva, Blasczyk, Arseniev, Köhl, Eiz-Vesper and Klöß. This is an 
open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these terms.
